BEAD-PC pairs digital cognitive testing with blood sampling in NHS primary care. Learn its study aims, practical relevance and evidence limits.
On October 6, 2026, Cambridge Cognition announced its participation in Imperial College London’s BEAD-PC study. Short for Blood Biomarkers for Early and Accurate Diagnosis of Alzheimer’s Disease in Primary Care, BEAD-PC includes CANTAB digital cognitive assessments alongside blood sampling.
According to the company’s announcement, BEAD-PC began in June 2026 and is planned to run for 15 months. It aims to recruit 500 people in North West London who have subjective memory complaints or symptoms of early cognitive decline.
The announced assessment route brings the testing into a primary-care pathway:
The study has two connected aims. It will assess whether combining cognitive assessment with blood-based biomarkers can support earlier and more accurate diagnosis. It will also examine how that combination could fit into NHS primary care.
That second question makes the setting part of the research. The work concerns both the information tests provide and how assessment could be organized for patients and clinicians. A testing tool and a workable route through care are related questions, but they are not the same question.
The NIHR Imperial Biomedical Research Centre supports the study. In a separate institutional report, it identifies Professor David Wingfield as BEAD-PC’s principal investigator.
Cambridge Cognition’s announcement also places BEAD-PC within the Davos Alzheimer’s Collaborative’s Healthcare System Preparedness Accurate Diagnosis programme.
The rationale is that blood biomarkers and cognitive assessments address different parts of the diagnostic question. In the announcement, Cambridge Cognition CEO Rob Baker described blood biomarkers as a way to identify biological signs of Alzheimer’s disease. He described digital cognitive assessments as a way to capture changes in thinking that matter in everyday life.
Cambridge Cognition describes CANTAB as providing an objective assessment of cognitive function. The proposed combination brings information about cognitive performance alongside information about disease biology.
Baker said bringing the two together in primary care has the potential to support diagnosis and clinical decision-making. This is the company’s explanation of why the combination is worth studying.
Professor Lefkos Middleton of Imperial College London focused on how diagnostic tools fit into care. In the announcement, he said such tools need to work within pathways that serve patients and clinicians while also fitting the wider health system. He described BEAD-PC as an effort to understand how the combined approach could be implemented at scale.
For readers, the distinction is useful: the research question is broader than whether a digital task or blood sample provides information. It also asks how that information could become part of an assessment process that works in primary care.
BEAD-PC sits within a wider period of NHS interest in dementia assessment. On October 2, 2026, UK Research and Innovation announced an up-to-£80 million Dementia Challenge involving nine technologies and practices to be tested in the NHS.
UKRI says the challenge aims for 92% of people to receive a dementia diagnosis within 18 weeks of referral. Its announcement puts the current figure at around 60%. These figures describe the challenge’s ambition and its stated comparison point, not an outcome from BEAD-PC.
One project within that challenge is led by the University of Oxford and Dementias Platform UK. According to UKRI, it is intended to integrate a panel of blood-based dementia biomarkers into NHS memory services.
That is a separate project from BEAD-PC. The connection is an interest in how diagnostic testing fits into NHS services. The projects should not be treated as one trial or as sharing findings.
This context helps explain why research about assessment pathways deserves attention. The question is not only which tools are available for testing, but how a health service might use their information in everyday care.
For participating primary-care teams, BEAD-PC sets out a referral route linking memory concerns with digital assessment and blood sampling at dedicated centres. The practical development is an organized research pathway, rather than simply the addition of another test.
For anyone concerned about changes in memory or thinking, the next step remains a conversation with a healthcare professional. The focus can be on what an assessment needs to clarify and how its findings would inform care.
Useful questions for that conversation include:
These are questions about the purpose of testing. They keep attention on how information will be used, rather than on obtaining a particular product or a single result.
Background on what cognitive assessments measure and the role of biomarkers within evaluation can help frame those discussions. Personal decisions about assessment belong with qualified care.
The announcement explains why BEAD-PC is being conducted. It does not establish that the combined approach has achieved its intended benefits. Several boundaries matter when interpreting the news.
Results have not been reported. Cambridge Cognition’s announcement gives no recruitment progress or diagnostic-accuracy figures. It also reports no participant outcomes. The recruitment target is a plan, not a confirmed number of people assessed.
Important methods remain unspecified. The announcement does not identify the blood biomarkers being tested or name a biomarker supplier. It does not provide detailed methods or diagnostic thresholds. It also does not describe a comparator group against which the combined approach would be assessed.
This is not routine screening. The study targets people with memory complaints or early cognitive symptoms. Healio’s coverage of blood-test guidance says current guidance does not recommend routine screening of people without memory or thinking problems. It also says blood tests should be used under clinician supervision within a broader evaluation, not treated as standalone diagnoses.
Diagnosis is different from prevention. BEAD-PC is evaluating diagnostic assessment. The study is not testing a way to prevent cognitive decline or preserve memory in otherwise healthy adults. Participation should not be described as a preventive intervention.
A research schedule is not an access date. The planned study period does not establish when this combined approach might become routine NHS care. The announcement provides no timetable for general availability.
The practical standard for following this research is straightforward: look for published findings and a clear account of how results were interpreted. The questions will be whether the combination supported assessment and how it worked within care. The novelty of the tools alone will not answer those questions.
The long-term importance of BEAD-PC lies in the question it puts to the test: how might information about cognitive performance and disease biology work together within primary care?
For cognitive-health research, that is a meaningful focus. New tests deserve attention not simply because they produce information, but because of what evidence shows about their place in care. BEAD-PC makes the organization of assessment part of the story alongside the tools themselves.
The next meaningful milestone is a clear account of the study’s findings and their relevance to people seeking help with memory concerns. That is the basis on which this approach should be judged.
Once attention turns from BEAD-PC’s design to interpreting future findings, FitBrainLab helps adults 60+ understand the research in clear language. The difficulty is separating established evidence from early testing claims; its coverage supports informed thinking about memory, focus and cognitive longevity while keeping uncertainty visible.
Follow FitBrainLab for research-led insights on memory, focus, brain aging, nutrition and mental fitness after 60. Stay connected for new articles, practical guidance and ideas for a sharper, more engaged life.
Build habits that support memory, focus and a curious, connected life.
Read the Blog
